Targeting a Common Pathway in Genetic Forms of Obesity

<p>At the end of November, the U.S. Food and Drug Administration approved Rhythm Pharmaceuticals Imcivree, the first therapy for chronic weight management in patients with certain genetic forms of obesity. The approval validates Rhythm’s approach to target a specific biological pathway common to a number of these conditions. We spoke David Meeker, CEO of Rhythm, about genetic obesities, the company’s drug Imcivree, and his plans to expand its use beyond the initial approved indications.</p>